Mangoceuticals Files S-1, Details Preferred Stock

TL;DR

Mangoceuticals S-1 is in, check out their preferred stock details and financials.

AI Summary

Mangoceuticals, Inc. filed an S-1 form on August 16, 2024, detailing its business operations and financial status. The company, located at 15110 Dallas Pkwy, Suite 600, Dallas, TX, operates in the health and allied services sector. Financial data for periods ending December 31, 2023, and June 30, 2024, are included, with specific mentions of Series B and Series C Convertible Preferred Stock.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Mangoceuticals' financial health and corporate structure as it potentially moves towards public trading.

Risk Assessment

Risk Level: medium — As an S-1 filing, it indicates a company preparing for an IPO or significant public offering, which inherently carries market and execution risks.

Key Numbers

• 20240816 — Filing Date (Date the S-1 form was officially filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st.)

Key Players & Entities

• MANGOCEUTICALS, INC. (company) — Filer of the S-1 document
• 15110 DALLAS PKWY, SUITE 600 (location) — Business and mailing address
• DALLAS, TX (location) — City and State of business address
• 8090 (industry_code) — Standard Industrial Classification code for Services-Misc Health & Allied Services, NEC
• MGRX:SeriesBConvertiblePreferredStockMember (financial_instrument) — Mentioned in financial data for 2022, 2023, and 2024
• MGRX:SeriesCConvertiblePreferredStockMember (financial_instrument) — Mentioned in financial data for 2022, 2023, and 2024

FAQ

Key Financial Figures

• $0.0001 — 7 shares of our common stock, par value $0.0001 per share consisting of (i) one million
• $0.50 — warrants issued at an exercise price of $0.50 per share (the "$0.50 Warrants"), (ii)
• $1.00 — warrants issued at an exercise price of $1.00 per share (the "$1.00 Warrants" and, to
• $1,100 — ith each share having a stated value of $1,100 and having an assumed conversion price
• $0.15 — conversion price of the floor price of $0.15 per share. Pursuant to the Securities P
• $0.32 — common stock as reported on Nasdaq was $0.32. We are an "emerging growth company"

Filing Documents

• forms-1.htm (S-1) — 4275KB
• ex3-5.htm (EX-3.5) — 4KB
• ex5-1.htm (EX-5.1) — 20KB
• ex23-1.htm (EX-23.1) — 8KB
• ex107.htm (EX-FILING FEES) — 45KB
• forms-1_001.jpg (GRAPHIC) — 11KB
• forms-1_002.jpg (GRAPHIC) — 2KB
• forms-1_003.jpg (GRAPHIC) — 79KB
• form10-k_005.jpg (GRAPHIC) — 27KB
• form10-k_006.jpg (GRAPHIC) — 49KB
• ex3-5_001.jpg (GRAPHIC) — 204KB
• ex3-5_002.jpg (GRAPHIC) — 86KB
• ex3-5_003.jpg (GRAPHIC) — 241KB
• ex3-5_004.jpg (GRAPHIC) — 46KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• ex23-1_001.jpg (GRAPHIC) — 6KB
• ex23-1_002.jpg (GRAPHIC) — 5KB
• 0001493152-24-032841.txt ( ) — 14479KB
• mgrx-20240630.xsd (EX-101.SCH) — 59KB
• mgrx-20240630_cal.xml (EX-101.CAL) — 64KB
• mgrx-20240630_def.xml (EX-101.DEF) — 360KB
• mgrx-20240630_lab.xml (EX-101.LAB) — 461KB
• mgrx-20240630_pre.xml (EX-101.PRE) — 408KB
• forms-1_htm.xml (XML) — 1745KB

UsE of PROCEEDS

UsE of PROCEEDS 64 DIVIDEND POLICY 64

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION RESULTS OF OPERATIONS 65

BUSINESS

BUSINESS 74 DETERMINATION OF OFFERING PRICE 94 MARKET PRICE OF COMMON STOCK AND RELATED STOCKHOLDER MATTERS 94

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 95 MANAGEMENT 97

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 107 Certain Relationships and Related Party Transactions 122 SELLING STOCKHOLDERS 127

Description of Capital Stock

Description of Capital Stock 128 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OF COMMON STOCK 133 PLAN OF DISTRIBUTION 134 Legal Matters 136 Experts 136 Where You Can Find More Information 136 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the "SEC"), using a "shelf" registration process. Under this shelf registration process, the selling stockholders may, from time to time, offer and sell shares of common stock offered under this prospectus. We will not receive any proceeds from the sale by the selling stockholders of the common stock offered by them described in this prospectus. We and the selling stockholders have not authorized anyone to provide any information or make any representations other than those contained in this prospectus. We and the selling stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson, or other person is authorized to give any information or to represent anything not contained in this prospectus. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is current only as of its date. Our business, financial condition, results of operations, and prospects may have changed since its date. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Co

View Full Filing

View this S-1 filing on SEC EDGAR